Well I'd guess that the current share price of GWPH could be compared to a penny stock.Let's see a .10 cent stock maybe expected to reach 3.00 "someday" by that reasoning this one at 45.00 potentially "someday" could be worth 1350.00 a share.Well,let's say they have a few forward splits in there and double or triple your shares.
Okay that was fun math speculation.......here's the facts from their website and if you can show me any other company in the entire stock market worldwide ,,,,,involved in the research of Marijuana trading on a world exchange I'd love to hear about it.If I said pink sheets and otcbb doesn't count then I guess you wouldn't have anything to say.
"GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy."
"GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW maintains in-house control over all aspects of the cannabinoid product development process - botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes."
Sativex®
"GW’s lead product, Sativex is now approved /recommended for approval in 24 countries. It is indicated as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. Sativex is also in Phase III clinical development for the treatment of cancer pain, the lead indication for the US market."
"GW has now entered into five separate licensing agreements for Sativex – with Bayer HealthCare in the UK and Canada; Almirall in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel." Cannabinoid Research
"GW occupies a world leading position in cannabinoid science and has developed an extensive international network of the most prominent scientists in the field. In mid 2007, GW’s early cannabinoid research activities were significantly expanded through the establishment of a global cannabinoid research agreement with Otsuka. Under this collaboration, GW and Otsuka are researching novel cannabinoids as potential treatments in the fields of Central Nervous System (CNS) disorders and oncology. In addition, GW has an in-house programme researching cannabinoids in the field of type 2 diabetes and related metabolic disorders. As part of this programme, GW set up in 2009 the GW Metabolic Research Laboratory at the University of Buckingham."
...........................
PARTNERS >>>>>
Otsuka Pharmaceutical Co. Ltd Consolidated sales were approximately USD 13 billion for fiscal year 2012. .... Novartis Pharma AG Novartis Group's continuing operations achieved net sales of USD 50.6 billion. .... Almirall S.A.
Almirall is Spain’s largest pharmaceutical company with sales approximating €1 billion .... Bayer HealthCare AG
This business employs 38,000 people and reported 2007 sales of €10.3bn. ....
Ipsen Pharma S.A.S
is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013 .... Neopharm Group
Established in 1941, the Neopharm Group is the 2nd largest marketing group in the Israeli health care market with 600 employees and $300M revenues.
"There are over 60 cannabinoid compounds identified to date. GW is researching a large number of cannabinoids, each of which has different effects and applications."
.....
So much more it is just insane to try and compare any other marijuana related company to this one.None are even close....not even.
Closest I can think of would be CAR* and it is still behind GW !!
Market Data 
Markets 
AI
